Dr. Matthew Melin, M.D.
Claim this profileClinical Trials Matthew Melin, M.D. is currently running
More about Matthew Melin, M.D.
Clinical Trial Related
1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Matthew Melin, M.D. has experience with
- Fuzzy Wale Compression Stockinet
Breakdown of trials Matthew Melin, M.D. has run
Peripheral Artery Disease
Peripheral Arterial Disease
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Melin, M.D. specialize in?
Matthew Melin, M.D. focuses on Peripheral Artery Disease and Peripheral Arterial Disease. In particular, much of their work with Peripheral Artery Disease has involved treating patients, or patients who are undergoing treatment.
Is Matthew Melin, M.D. currently recruiting for clinical trials?
Yes, Matthew Melin, M.D. is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Matthew Melin, M.D. has studied deeply?
Yes, Matthew Melin, M.D. has studied treatments such as Fuzzy Wale Compression Stockinet.
What is the best way to schedule an appointment with Matthew Melin, M.D.?
Apply for one of the trials that Matthew Melin, M.D. is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.